King's College London

Research portal

Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)241-243
Number of pages3
JournalAntiviral therapy
Volume25
Issue number5
DOIs
Published2020

Bibliographical note

Copyright: This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

King's Authors

Abstract

Several antiretrovirals including dolutegravir, rilpivirine and cobicistat inhibit tubular creatinine secretion, leading to benign increases in serum creatinine and reductions in estimated glomerular filtration rate (eGFR). This commentary discusses the magnitude and pattern of eGFR decline, whether this can be overcome by applying a standardized correction factor (as reported by Brunet et al. in Antiviral Therapy), the value of serial eGFR measures to detect rapid eGFR decline and the potential utility of cystatin C as an alternative biomarker of kidney function.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454